**Introduction to HER2- BC and HER2 Mechanism**

|  |  |
| --- | --- |
| Citation | Address |
| Arnold A, Papanikolaou A. Cyclin D1 in breast cancer pathogenesis. *J Clin Oncol*. 2005;23:4215-4224. | https://pubmed.ncbi.nlm.nih.gov/15961768/ |
| Baselga J, Campone M, Piccart M, et al. Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. *N Engl J Med*. 2012;366:520-529. | <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5705195/> |
| Beatson GT. On the treatment of inoperable cases of carcinoma of the mamma: suggestions for a new method of treatment, with illustrative cases. *Trans Med Chir Soc Edinb*. 1896;15:153-179. | <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5518378/> |
| Cohen MH, Hirschfeld S, Flamm Honig S, et al. Drug approval summaries: Arsenic trioxide, tamoxifen citrate, anastrazole, paclitaxel, bexarotene. *Oncologist*. 2001;6:4-11. | https://pubmed.ncbi.nlm.nih.gov/11161223 |
| Fareston (toremifene citrate) [package insert]. Bedminster, NJ; Kyowa Kirin Inc; Revised May 5, 2017. | <http://fareston.com/uploads/documents/fareston-pi.pdf> |
| Finn RS, Crown JP, Lang I, et al. The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): A randomised phase 2 study. *Lancet Oncol*. 2015;16:25-35. | <https://pubmed.ncbi.nlm.nih.gov/25524798/> |
| Fulvestrant (faslodex) [package insert]. Wilmington, DE; AstraZeneca Pharmaceuticals LP; Revised August 2020. | <https://medicalinformation.astrazeneca-us.com/home/prescribing-information/faslodex-pi.html> |
| Hortobagyi GN, Stemmer SM, Burris HA, et al. Ribociclib as first-line therapy for HR-positive, advanced breast cancer. *N Engl J Med*. 2016;375:1738-1748. | <https://pubmed.ncbi.nlm.nih.gov/27717303/> |
| Ibrance (palbociclib) [package insert]. New York, NY; Pfizer Inc; Revised September 2019. | <https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/207103Orig1s012lbl.pdf> |
| Ingham M, Schwartz GK. Cell-cycle therapeutics come of age. *J Clin Oncol*. 2017;35:2949-2959. | <https://pubmed.ncbi.nlm.nih.gov/28580868/> |
| Kisqali (ribociclib) [package insert]. East Hanover, New Jersey; Novartis Pharmaceuticals Corporation; Revised July 2020. | <https://www.novartis.us/sites/www.novartis.us/files/kisqali.pdf> |
| Lynce F, Shajahan-Haq AN, Swain SM. CDK4/6 inhibitors in breast cancer therapy: Current practice and future opportunities. *Pharmacol Ther*. 2018;191:65-73. | <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6533626/> |
| Musgrove EA, Caldon CE, Barraclough J, Stone A, Sutherland RL. Cyclin D as a therapeutic target in cancer. *Nat Rev Cancer.* 2011;11:558-572. | <https://pubmed.ncbi.nlm.nih.gov/21734724/> |
| Sledge GW Jr, Toi M, Neven P, et al. MONARCH 2: Abemaciclib in combination with fulvestrant in women with HR+/HER2- advanced breast cancer who had progressed while receiving endocrine therapy. *J Clin Oncol*. 2017;35:2875-2884. | <https://pubmed.ncbi.nlm.nih.gov/28580882/> |
| Verzenio (abemaciclib) [package insert]. Indianapolis, IN; Eli Lilly & Co; Revised March 2020. | <http://pi.lilly.com/us/verzenio-uspi.pdf> |
| What is Advanced, Metastatic and Stage 3 & 4 Breast Cancer? Advanced Breast Cancer Community. Accessed August 22, 2020. | <http://www.advancedbreastcancercommunity.org/understanding-abc> |
| Yu Q, Sicinska E, Geng Y, et al. Requirement for CDK4 kinase function in breast cancer. *Cancer Cell*. 2006;9:23-32. | <https://pubmed.ncbi.nlm.nih.gov/16413469/> |

**1st Line Treatment with CDK 4/6 Inhibitors**

|  |  |
| --- | --- |
| Citation | Address |
| Fan W, Chang J, Fu P. Endocrine therapy resistance in breast cancer: Current status, possible mechanisms and overcoming strategies. *Future Med Chem*. 2015;7:1511-1519. | <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5558537/> |
| Finn RS, Martin M, Rugo HS, et al. Palbociclib and letrozole in advanced breast cancer. *N Engl J Med*. 2016;375:1925-1936. | <https://pubmed.ncbi.nlm.nih.gov/27959613/> |
| Goetz MP, Toi M, Campone M, et al. MONARCH 3: Abemaciclib as initial therapy for advanced breast cancer. *J Clin Oncol*. 2017;35:3638-3646. | <https://pubmed.ncbi.nlm.nih.gov/28968163/> |
| Hortobagyi GN, Stemmer SM, Burris HA, et al. Ribociclib as first-line therapy for HR-positive, advanced breast cancer. *N Engl J Med.* 2016;375:1738-1748. | <https://pubmed.ncbi.nlm.nih.gov/27717303/> |
| Hortobagyi GN, Stemmer SM, Burris HA, et al. Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer. *Ann Oncol.* 2018;29:1541-1547. | <https://pubmed.ncbi.nlm.nih.gov/29718092/> |
| Johnston S, Martin M, Di Leo A, et al. MONARCH 3 final PFS: A randomized study of abemaciclib as initial therapy for advanced breast cancer. *NPJ Breast Cancer*. 2019;5:5. | <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6336880/> |
| National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Breast Cancer. Version 5.2020. Published July 15, 2020 | <https://www.nccn.org/professionals/physician_gls/pdf/breast.pdf> |
| Osborne CK, Schiff R. Mechanisms of endocrine resistance in breast cancer. *Annu Rev Med*. 2011;62:233-247. | <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3656649/> |
| O'Shaughnessy J, Petrakova K, Sonke GS, et al. Ribociclib plus letrozole versus letrozole alone in patients with de novo HR+, HER2- advanced breast cancer in the randomized MONALEESA-2 trial. *Breast Cancer Res Treat*. 2018;168:127-134. | <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5847028/> |
| Rugo HS, Finn RS, Diéras V, et al. Palbociclib plus letrozole as first-line therapy in estrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer with extended follow-up. *Breast Cancer Res Treat*. 2019;174:719-729. | <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6438948/> |
| Tripathy D, Im SA, Colleoni M, et al. Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): A randomised phase 3 trial. *Lancet Oncol.* 2018;19:904-915. | <https://pubmed.ncbi.nlm.nih.gov/29804902/> |

**Ribociclib in Premenopausal 1st-Line Metastatic Breast Cancer**

|  |  |
| --- | --- |
| Citation | Address |
| Bidard FC, Callens C, Dalenc F. Prognostic impact of ESR1 mutations in ER+ HER2- MBC patients prior treated with first line AI and palbociclib: An exploratory analysis of the PADA-1 trial. *J Clin Oncol*. 2020;38(15 suppl):1010 | [**https://ascopubs.org/doi/abs/10.1200/JCO.2020.38.15\_suppl.1010**](https://ascopubs.org/doi/abs/10.1200/JCO.2020.38.15_suppl.1010) |
| Chandarlapaty S, Chen D, He W, et al. Prevalence of *ESR1* mutations in cell-free DNA and outcomes in metastatic breast cancer: A secondary analysis of the BOLERO-2 clinical trial. *JAMA Oncol*. 2016;2:1310-1315. | [**https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5063698/**](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5063698/) |
| Fribbens C, O'Leary B, Kilburn L, et al. Plasma ESR1 mutations and the treatment of estrogen receptor-positive advanced breast cancer. *J Clin Oncol*. 2016;34:2961-2968. | [**https://pubmed.ncbi.nlm.nih.gov/27269946/**](https://pubmed.ncbi.nlm.nih.gov/27269946/) |
| Hortobagyi GN, Stemmer SM, Burris HA, et al. Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer. *Ann Oncol.* 2018;29:1541-1547. | [**https://pubmed.ncbi.nlm.nih.gov/29718092/**](https://pubmed.ncbi.nlm.nih.gov/29718092/) |
| Hurvitz SA, Im SA, Lu YS, et al. Phase III MONALEESA-7 trial of premenopausal patients with HR+/HER2− advanced breast cancer (ABC) treated with endocrine therapy ± ribociclib: Overall survival (OS) results. *J Clin Oncol*. 2019;37(18 suppl):LBA1008 | [**https://ascopubs.org/doi/abs/10.1200/JCO.2019.37.18\_suppl.LBA1008**](https://ascopubs.org/doi/abs/10.1200/JCO.2019.37.18_suppl.LBA1008) |
| Im SA, Lu YS, Bardia A, et al. Overall survival with ribociclib plus endocrine therapy in breast cancer. *N Engl J Med*. 2019;381:307-316. | [**https://pubmed.ncbi.nlm.nih.gov/31166679/**](https://pubmed.ncbi.nlm.nih.gov/31166679/) |
| Jeannot E, Darrigues L, Michel M, et al. A single droplet digital PCR for ESR1 activating mutations detection in plasma. *Oncogene*. 2020;39):2987-2995. | [**https://pubmed.ncbi.nlm.nih.gov/32042112/**](https://pubmed.ncbi.nlm.nih.gov/32042112/) |
| Spoerke JM, Gendreau S, Walter K, et al. Heterogeneity and clinical significance of *ESR1* mutations in ER-positive metastatic breast cancer patients receiving fulvestrant. *Nat Commun*. 2016;7:11579. | [**https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4869259/**](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4869259/) |
| Tripathy D, Im SA, Colleoni M, et al. Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): A randomised phase 3 trial. *Lancet Oncol.* 2018;19:904-915. | [**https://pubmed.ncbi.nlm.nih.gov/29804902/**](https://pubmed.ncbi.nlm.nih.gov/29804902/) |

**CDK4/6 Inhibitors Combined with Fulvestrant**

|  |  |
| --- | --- |
| Citation | Address |
| Cristofanilli M, Slamon DJ, Ro J, et al. Overall survival (OS) with palbociclib plus fulvestrant in women with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2−) advanced breast cancer (ABC): Analyses from PALOMA-3. *Ann Oncol.* 2018;29(suppl 8):viii708. | [https://www.annalsofoncology.org/article/S0923-7534(19)50400-8/fulltext](https://www.annalsofoncology.org/article/S0923-7534%2819%2950400-8/fulltext) |
| Cristofanilli M, Turner NC, Bondarenko I, et al. Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): Final analysis of the multicentre, double-blind, phase 3 randomised controlled trial. *Lancet Oncol.* 2016;17:425-439. | <https://pubmed.ncbi.nlm.nih.gov/26947331/> |
| Jhaveri KL. No clear survival benefit for fulvestrant versus letrozole in combination with palbociclib for endocrine-sensitive metastatic breast cancer [news release]. *ASCO Daily News*. Published May 29, 2020. | <https://dailynews.ascopubs.org/do/10.1200/ADN.20.200189/full/> |
| Llombart-Cussac A, Perez-Garcia JM, Bellet M, et al. PARSIFAL: A randomized, multicenter, open-label, phase II trial to evaluate palbociclib in combination with fulvestrant or letrozole in endocrine-sensitive patients with estrogen receptor (ER)[+}/HER2[-] metastatic breast cancer. *J Clin Oncol*. 2020;38(15 suppl):1007. | <https://ascopubs.org/doi/abs/10.1200/JCO.2020.38.15_suppl.1007> |
| Slamon DJ, Neven P, Chia S, et al. Overall survival with ribociclib plus fulvestrant in advanced breast cancer. *N Engl J Med*. 2020;382:514-524. | [h](https://www.nejm.org/doi/10.1056/NEJMoa1911149?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%20%200pubmed)<https://pubmed.ncbi.nlm.nih.gov/31826360/> |
| Slamon DJ, Neven P, Chia S, et al. Phase III randomized study of ribociclib and fulvestrant in hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: MONALEESA-3. *J Clin Oncol.* 2018;36:2465-2472. | <https://ascopubs.org/doi/10.1200/JCO.2018.78.9909?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%20%200pubmed><https://pubmed.ncbi.nlm.nih.gov/29860922/> |
| Sledge GW Jr, Toi M, Neven P, et al. MONARCH 2: Abemaciclib in combination with fulvestrant in women with HR+/HER2- advanced breast cancer who had progressed while receiving endocrine therapy. *J Clin Oncol*. 2017;35:2875-2884. | <https://pubmed.ncbi.nlm.nih.gov/28580882/> |
| Sledge GW Jr, Toi M, Neven P, et al. The effect of abemaciclib plus fulvestrant on overall survival in hormone receptor-positive, ERBB2-negative breast cancer that progressed on endocrine therapy-MONARCH 2: A randomized clinical trial. *JAMA Oncol.* 2019;6:116-124. | <https://pubmed.ncbi.nlm.nih.gov/31563959/> |
| Turner NC, Slamon DJ, Ro J, et al. Overall survival with palbociclib and fulvestrant in advanced breast cancer. *N Engl J Med*. 2018;379:1926-1936. | <https://pubmed.ncbi.nlm.nih.gov/30345905/> |

**Abemaciclib and CDK4/6 Inhibitors vs Chemotherapy**

|  |  |
| --- | --- |
| Citation | Address |
| Hamilton E, Cortes J, Dieras V. Abstract PD1-11: nextMONARCH 1: Phase 2 study of abemaciclib plus tamoxifen or abemaciclib alone in HR+, HER2- advanced breast cancer. *Cancer Res.* 2019:79(4 Suppl):PD1-11. | <https://cancerres.aacrjournals.org/content/79/4_Supplement/PD1-11> |
| Martín M, Zielinski C, Ruíz-Borrego M, et al. Abstract GS2-07: Results from PEARL study (GEICAM/2013-02\_CECOG/BC.1.3.006): A phase 3 trial of palbociclib (PAL) in combination with endocrine therapy (ET) versus capecitabine (CAPE) in hormonal receptor (HR)-positive/human epidermal growth factor receptor (HER) 2-negative metastatic breast cancer (MBC) patients (pts) whose disease progressed on aromatase inhibitors (AIs). *Cancer Res*. 2020;80(4 suppl):GS2-07. | <https://cancerres.aacrjournals.org/content/80/4_Supplement/GS2-07> |
| NCT02028507. Phase III Palbociclib With Endocrine Therapy vs. Capecitabine in HR+/HER2- MBC With Resistance to Aromatase Inhibitors (PEARL). | <https://clinicaltrials.gov/ct2/show/NCT02028507> |

**Monitoring and Managing Toxicities associated with CDK 4/6 Inhibition**

|  |  |
| --- | --- |
| Citation | Address |
| Cristofanilli M, Turner NC, Bondarenko I, et al. Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): Final analysis of the multicentre, double-blind, phase 3 randomised controlled trial. *Lancet Oncol.* 2016;17:425-439. | <https://pubmed.ncbi.nlm.nih.gov/26947331/> |
| Finn RS, Martin M, Rugo HS, et al. Palbociclib and letrozole in advanced breast cancer. *N Engl J Med*. 2016;375:1925-1936. | <https://pubmed.ncbi.nlm.nih.gov/27959613/> |
| Hortobagyi GN, Stemmer SM, Burris HA, et al. Ribociclib as first-line therapy for HR-positive, advanced breast cancer. *N Engl J Med*. 2016;375:1738-1748. | <https://pubmed.ncbi.nlm.nih.gov/27717303/> |
| Ibrance (palbociclib) [package insert]. New York, NY; Pfizer Inc; Revised September 2019. | <https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/207103Orig1s012lbl.pdf> |
| Johnston S, Martin M, Di Leo A, et al. MONARCH 3 final PFS: A randomized study of abemaciclib as initial therapy for advanced breast cancer. *NPJ Breast Cancer*. 2019;5:5. | <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6336880/> |
| Kisqali (ribociclib) [package insert]. East Hanover, New Jersey; Novartis Pharmaceuticals Corporation; Revised July 2020. | <https://www.novartis.us/sites/www.novartis.us/files/kisqali.pdf> |
| Verma S, Bartlett CH, Schnell P, et al. Palbociclib in combination with fulvestrant in women with hormone receptor-positive/HER2-negative advanced metastatic breast cancer: Detailed safety analysis from a multicenter, randomized, placebo-controlled, phase III study (PALOMA-3). *Oncologist*. 2016;21:1165-1175. | <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5061543/> |
| Verzenio (abemaciclib) [package insert]. Indianapolis, IN; Eli Lilly & Co; Revised March 2020. | <http://pi.lilly.com/us/verzenio-uspi.pdf> |

**Multidisciplinary Team Tools**

|  |  |
| --- | --- |
| Citation | Address |
| Agency for Healthcare Research and Quality. The SHARE Approach Essential Steps of Shared Decisionmaking: Quick Reference Guide. Published April 2014. | <https://www.ahrq.gov/sites/default/files/wysiwyg/professionals/education/curriculum-tools/shareddecisionmaking/tools/tool-1/share-tool1.pdf> |
| Agency for Healthcare Research and Quality. The CAHPS Ambulatory Care Improvement Guide: Practical Strategies for Improving Patient Experience; Section 6: Strategies for Improving Patient Experience with Ambulatory Care. Updated July 2017. | <https://www.ahrq.gov/sites/default/files/wysiwyg/cahps/quality-improvement/improvement-guide/6-strategies-for-improving/communication/cahps-strategy-section-6-i.pdf> |
| Agency for Healthcare Research and Quality. The SHARE Approach: A Model for Shared Decision Making. Published April 2016. | <https://www.ahrq.gov/sites/default/files/publications/files/share-approach_factsheet.pdf> |
| Stacey D, Légaré F, Lewis K, et al. Decision aids for people facing health treatment or screening decisions. *Cochrane Database Syst Rev*. 2017;4:CD001431. | <https://pubmed.ncbi.nlm.nih.gov/24470076/> |
| Moore S and Brandt ML. Adherence to Oral Therapies for Cancer: Helping Your Patients Stay on Course Toolkit. *Oncology Nursing Society.*2010. Accessed August 23, 2020. | <http://msho.org/aws/MSHO/asset_manager/get_file/44984> |
| Mehta P, Haggstrom DA, Latini DM, et al. Cancer survivorship care: Summarizing the 6 tools for success. *Fed Pract.* 2011;28(Suppl 6):43S-49S. | <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4429039/> |
| Miller KD, Siegel RL, Lin CC, et al. Cancer treatment and survivorship statistics, 2016. *CA Cancer J Clin.* 2016;66:271-289. | <https://pubmed.ncbi.nlm.nih.gov/27253694/> |
| Miller KD, Nogueira L, Mariotto AB, et al. Cancer treatment and survivorship statistics, 2019. *CA Cancer J Clin.* 2019;69:363-385. | <https://pubmed.ncbi.nlm.nih.gov/31184787/> |